METIMYD Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Metimyd, and what generic alternatives are available?
Metimyd is a drug marketed by Schering and is included in one NDA.
The generic ingredient in METIMYD is prednisolone acetate; sulfacetamide sodium. There are eighty-eight drug master file entries for this compound. Additional details are available on the prednisolone acetate; sulfacetamide sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for METIMYD?
- What are the global sales for METIMYD?
- What is Average Wholesale Price for METIMYD?
Summary for METIMYD
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 114 |
DailyMed Link: | METIMYD at DailyMed |
US Patents and Regulatory Information for METIMYD
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Schering | METIMYD | prednisolone acetate; sulfacetamide sodium | OINTMENT;OPHTHALMIC | 010210-002 | Sep 9, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Schering | METIMYD | prednisolone acetate; sulfacetamide sodium | SUSPENSION/DROPS;OPHTHALMIC | 010210-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |